Overview
Sickle cell-beta^0^-thalassemia is a genetic disorder characterized by the co-occurrence of sickle cell disease and the absence of beta-globin chain production, leading to severe hemolytic anemia and complications typical of both conditions 1.Diagnosis
Hemoglobin electrophoresis confirms the presence of sickle hemoglobin (HbS) and absence of beta-globin chains 1.
Complete blood count (CBC) typically shows microcytic anemia, hemoglobin levels often below 8 g/dL, and variable proportions of sickle cells 1.
Reticulocyte count is usually elevated due to increased hemolysis 1.
Genetic testing confirms the beta^0^-thalassemia mutation 1.Management
Hydroxyurea is recommended to increase fetal hemoglobin (HbF) production, reducing vaso-occlusive crises and hospitalizations 1.
Blood transfusions may be required for severe anemia or acute complications 1.
Pain management with opioids for vaso-occlusive crises, alongside non-opioid analgesics for chronic pain 1.
Regular monitoring for complications such as stroke, acute chest syndrome, and organ damage 1.Special Populations
Pregnancy: Management focuses on preventing complications like preeclampsia and ensuring adequate fetal growth; close monitoring and possibly increased transfusion support are advised 1.
Pediatrics: Early initiation of hydroxyurea and regular screening for developmental delays and organ dysfunction are crucial 1.
Elderly: Management emphasizes palliative care and symptom control, with a focus on chronic pain management and supportive care 1.
Comorbidities: Specific attention to organ involvement (e.g., renal, cardiac) with tailored interventions; regular multidisciplinary assessments are recommended 1.Key Recommendations
Initiate hydroxyurea therapy to increase HbF levels and reduce clinical complications (Evidence: Strong) 1.
Regular hemoglobin electrophoresis and CBC monitoring to assess disease severity and response to treatment (Evidence: Moderate) 1.
Implement prophylactic blood transfusions in patients with severe anemia or high risk of complications (Evidence: Moderate) 1.References
1 Gruson D, Lindberg C. Laboratory medicine: the precursors strike back. Acta clinica Belgica 2011. link
2 Baorto DM, Cimino JJ, Parvin CA, Kahn MG. Using Logical Observation Identifier Names and Codes (LOINC) to exchange laboratory data among three academic hospitals. Proceedings : a conference of the American Medical Informatics Association. AMIA Fall Symposium 1997. link